Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study Transcript

Operator

Hello, everyone, and thank you for joining us today for the IL-15 Celiac Disease Phase 2a Topline Results Conference Call. My name is Sami, and I’ll be coordinating your call today. [Operator Instructions] I’ll now hand over to your host, Christopher Stevo, Head of IR, to begin. Please go ahead, Christopher.

Christopher Stevo
Senior Vice President of Investor Relations & Competitive Intelligence

Thanks, Sami. Good morning, and good afternoon, everyone. Thank you for joining us for the celiac disease results for TEV-‘408 (Anti-IL-15). The materials are posted to our website this morning in the Investor Relations section, as always, please see those.

And before I turn the call over to Richard Francis, I’d like to remind everyone that we’ll be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors.

These factors are described in our earnings press release